NeoGenomics Inc
$ 11.15
-2.79%
12 Jun - close price
- Market Cap 1,451,861,000 USD
- Current Price $ 11.15
- High / Low $ 11.57 / 10.99
- Stock P/E N/A
- Book Value 6.49
- EPS -0.77
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.12 %
- 52 Week High 13.74
- 52 Week Low 4.72
About
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Analyst Target Price
$15.06
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-17 | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-18 | 2024-11-05 | 2024-07-29 | 2024-04-30 | 2024-02-20 | 2023-11-06 | 2023-08-08 |
| Reported EPS | 0.01 | 0.06 | 0.03 | 0.03 | -0.2035 | 0.04 | -0.1394 | 0.03 | -0.02 | 0.03 | -0.02 | -0.05 |
| Estimated EPS | 0.0114 | 0.04 | 0.02 | 0.02 | -0.01 | 0.0286 | 0.01 | -0.0023 | -0.05 | -0.03 | -0.08 | -0.11 |
| Surprise | -0.0014 | 0.02 | 0.01 | 0.01 | -0.1935 | 0.0114 | -0.1494 | 0.0323 | 0.03 | 0.06 | 0.06 | 0.06 |
| Surprise Percentage | -12.2807% | 50% | 50% | 50% | -1935% | 39.8601% | -1494% | 1404.3478% | 60% | 200% | 75% | 54.5455% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NEO
2026-06-11 20:39:20
Neogenomics (NEO) director Lynn A. Tetrault sold 5,307 common shares at $11.29 per share on June 9, 2026. Following the sale, she still directly holds 91,422 common shares and indirectly holds 7,000 shares through an IRA. Tetrault also retains significant equity awards, including restricted stock units and multiple stock options with various exercise prices and expiration dates.
2026-06-09 20:40:09
This article details an SEC Form 144 filing by NEOGENOMICS INC (NEO), indicating a proposed sale of 5,307 shares of common stock with an aggregate market value of $58,111.65. The filing shows that the securities were acquired on June 1, 2026, as restricted stock units from the Issuer, with Morgan Stanley Smith Barney LLC as the broker. The filing also notes that no securities of the issuer were sold during the past three months by the person for whose account the securities are to be sold.
2026-06-05 20:04:00
This article analyzes Neogenomics Inc. (NYSE: NEO) using AI models, highlighting strong sentiment across all horizons and an exceptional 82.0:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, with specific entry, target, and stop-loss levels. The analysis provides multi-timeframe signal strengths, support, and resistance levels for near-term, mid-term, and long-term outlooks.
2026-06-04 04:39:32
NeoGenomics director Lynn A. Tetrault increased her holdings by exercising 23,077 restricted stock units at $0.00 per share, bringing her direct Common Stock ownership to 96,729 shares. She also received new equity compensation comprising 15,970 Restricted Stock Units and 11,069 Stock Options with an exercise price of $10.52, both vesting or becoming exercisable on June 1, 2027. Additionally, she holds 7,000 shares indirectly and maintains several pre-existing stock option positions.
2026-06-04 04:39:32
NeoGenomics director Michael Aaron Kelly reported equity compensation activity, including exercising 23,077 restricted stock units (RSUs) into common stock, increasing his direct holdings to 67,086 shares. He also received new grants of 15,970 RSUs and 11,069 stock options, both vesting in June 2027. This activity, detailed in a Form 4 filing, reflects compensation-related transactions rather than discretionary market trading.
2026-06-04 00:10:11
Felicia Williams, a director at NeoGenomics, Inc. (NEO), recently increased her holdings through the exercise of restricted stock units (RSUs) and new equity grants. She exercised 23,077 common shares from RSUs, bringing her direct ownership to 30,237 shares. Additionally, Williams was granted 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share.
